The DCXR Knockout Raji Polyclonal Cells product comprises a population of human Raji B lymphocytes engineered via CRISPR/Cas9-mediated disruption of the DCXR gene, generating a heterogeneous pool of DCXR-deficient cells. This polyclonal knockout format provides a robust loss-of-function model for investigating DCXR-dependent metabolic and detoxification pathways without clonal selection artifacts. The cells are delivered as a ready-to-use suspension culture, retaining the parental line’s non-adherent growth properties and Epstein-Barr virus (EBV)-positive background, enabling immediate application in a wide array of functional assays.
Raji cells are an EBV-positive Burkitt’s lymphoma-derived B lymphocyte line widely employed in immunology and cancer research. They exhibit characteristics of mature B cells, including surface immunoglobulin expression and the capacity for antigen presentation and antibody production. As a suspension cell line, Raji cells are well-suited for high-throughput assays, flow cytometry, and scalable culture protocols. Their lymphoblastoid phenotype makes them an established model for studying B-cell signaling, viral oncogenesis, and humoral immunity, and the introduction of a DCXR knockout extends their utility to metabolic and redox biology inquiries.
DCXR encodes dicarbonyl/L-xylulose reductase, an enzyme that catalyzes the NADPH-dependent reduction of L-xylulose to xylitol within the pentose and glucuronate interconversions pathway, and also detoxifies reactive dicarbonyl species such as methylglyoxal and 3-deoxyglucosone. The enzyme is regulated by upstream factors including Glucose, Insulin, and the transcription factor ChREBP, which modulate its expression in response to metabolic cues. DCXR interacts with NADPH as a cofactor and shares functional overlap with aldose reductase and carbonyl reductase. Downstream, its activity maintains cellular redox balance by preventing accumulation of cytotoxic carbonyls, while xylitol production intersects with carbohydrate metabolism. Disruption of DCXR abolishes these protective reactions, leading to heightened sensitivity to carbonyl stress and altered pentose flux.
In the context of Raji B lymphocytes, DCXR knockout creates a uniquely vulnerable metabolic state. B cells are exposed to fluctuating nutrient and oxidative environments during immune responses, and their survival and proliferation depend on efficient detoxification pathways. Loss of DCXR function is predicted to impair the elimination of endogenously generated reactive carbonyls, which can form advanced glycation end products and trigger apoptosis or genomic instability. This model therefore holds particular significance for exploring mechanisms of chemoresistance in lymphoma, as carbonyl detoxification has been implicated in cancer cell survival upon treatment with alkylating agents or oxidative stressors. Additionally, it provides a platform to dissect the interplay between pentose metabolism and malignant B-cell physiology.
Researchers can employ DCXR Knockout Raji Polyclonal Cells in a diverse range of experiments. Typical applications include investigating carbonyl detoxification in B cells through viability assays (MTT) following methylglyoxal challenge, assessing apoptosis via Annexin V flow cytometry, and profiling metabolic alterations using LC-MS-based metabolomics. The cells support functional analysis of DCXR in drug resistance by testing sensitivity to chemotherapeutic agents. Complementary techniques such as Western blotting, RT-qPCR, and xylulose reductase activity assays allow molecular and biochemical validation. The polyclonal knockout population is suitable for studying pentose and glucuronate pathway dynamics in a lymphoma background. For personalized support and further information, please contact Ascent Research.
